Hempel JM, Sprinzl G, Riechelmann H, et al. - Researchers conducted this investigation to assess the long-term safety and efficiency of an active middle ear implant (AMEI) in treating hearing loss in children and adolescents with a primary focus on improving speech discrimination. Participants in the study were 31 pediatric patients aged 5 to 17 years. Children between 5 and 9 years of age improved in WRS from 21.92 to 95.38% and in SRT in quiet and in noise from 62.45 dB SPL (sound pressure level) and +1.14 dB SNR to 42.07 dB SPL and −4.45 dB SNR respectively. Adolescents between 10 and 17 years of age improved in WRS from 12.78% to 84.71% and in SRT in quiet and in noise from 63.96 dB SPL and +3.32 dB SNR to 35.31 dB SPL and −4.55 dB SNR respectively. Findings suggested that the AMEI under investigation is a safe treatment for children and adolescents and has significantly improved audiological performance that remains stable on a long-term scale (up to 36 mo postimplantation). In particular, all problems and questions concerning safety and performance related to adults can also be applied to the pediatric population, as no obvious specific issues have arisen.